GlassScriptPhysician profile
Brandon Geosling
NPI 1538522982
$485.22
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.88 · 2020: $212 · 2021: $170 · 2022: $11.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $182.39 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $97.15 | 2020 | |
| Btg International INC. | $89.32 | 2020 | |
| Pfizer INC. | $47.75 | 2019 | |
| La Jolla Pharmaceutical Company | $43.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.48 | 2021-2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Geosling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.